126 related articles for article (PubMed ID: 36120242)
1. Expression of SOX10 in Triple-Negative Breast Carcinoma in Pakistan.
Ali S; Rathore Z; Rafique Z; Chughtai AS; Atiq A
Cureus; 2022 Aug; 14(8):e27938. PubMed ID: 36120242
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological significance of Sox10 expression in triple-negative breast carcinoma.
Jin L; Qin C; Qi X; Hong T; Yang X; Zhu X
Transl Cancer Res; 2020 Sep; 9(9):5603-5613. PubMed ID: 35117924
[TBL] [Abstract][Full Text] [Related]
3. Sry-related high-mobility-group/HMG box 10 (SOX10) as a sensitive marker for triple-negative breast cancer.
Jamidi SK; Hu J; Aphivatanasiri C; Tsang JY; Poon IK; Li JJ; Chan SK; Cheung SY; Tse GM
Histopathology; 2020 Dec; 77(6):936-948. PubMed ID: 32304249
[TBL] [Abstract][Full Text] [Related]
4. Utility of Sox10 labeling in metastatic breast carcinomas.
Nelson ER; Sharma R; Argani P; Cimino-Mathews A
Hum Pathol; 2017 Sep; 67():205-210. PubMed ID: 28843711
[TBL] [Abstract][Full Text] [Related]
5. SOX10, GATA3, GCDFP15, Androgen Receptor, and Mammaglobin for the Differential Diagnosis Between Triple-negative Breast Cancer and TTF1-negative Lung Adenocarcinoma.
Laurent E; Begueret H; Bonhomme B; Veillon R; Thumerel M; Velasco V; Brouste V; Hoppe S; Fournier M; Grellety T; MacGrogan G
Am J Surg Pathol; 2019 Mar; 43(3):293-302. PubMed ID: 30628926
[TBL] [Abstract][Full Text] [Related]
6. High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers.
Yoon EC; Wilson P; Zuo T; Pinto M; Cole K; Harigopal M
Hum Pathol; 2020 Aug; 102():13-22. PubMed ID: 32565323
[TBL] [Abstract][Full Text] [Related]
7. SOX10 expression in mammary invasive ductal carcinomas and benign breast tissue.
Chiu K; Ionescu DN; Hayes M
Virchows Arch; 2019 Jun; 474(6):667-672. PubMed ID: 30903273
[TBL] [Abstract][Full Text] [Related]
8. A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancer.
Tozbikian GH; Zynger DL
Hum Pathol; 2019 Mar; 85():221-227. PubMed ID: 30468800
[TBL] [Abstract][Full Text] [Related]
9. [Diagnostic value of combined application of GATA3, SOX10 and p16 in triple negative breast carcinomas].
Zhang DM; Zhai CJ; Feng XD; Wang CZ; Qiu JF; Wei JG
Zhonghua Yi Xue Za Zhi; 2022 Mar; 102(10):735-740. PubMed ID: 35280018
[No Abstract] [Full Text] [Related]
10. SRY-box transcription factor 10 is a highly specific biomarker of basal-like breast cancer.
Klaric KA; Riaz N; Asleh K; Wang XQ; Atalla T; Strickland S; Nielsen TO; Kos Z
Histopathology; 2022 Feb; 80(3):589-597. PubMed ID: 34725848
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical Profile of Triple-Negative Breast Cancers: SOX10 and AR Dual Negative Tumors Have Worse Outcomes.
Rammal R; Goel K; Motanagh SA; Carter GJ; Clark BZ; Fine JL; Harinath L; Villatoro TM; Yu J; Bhargava R
Mod Pathol; 2024 May; 37(7):100517. PubMed ID: 38763422
[TBL] [Abstract][Full Text] [Related]
12. Combination of GATA3, SOX-10, and PAX8 in a Comprehensive Panel to Diagnose Breast Cancer Metastases.
Na K; Woo HY; DO SI; Kim SW
In Vivo; 2022; 36(1):473-481. PubMed ID: 34972751
[TBL] [Abstract][Full Text] [Related]
13. Combined use of SOX10 and GATA3 in mammary carcinoma.
Qazi MS; McGregor SM
Pathol Res Pract; 2020 Feb; 216(2):152801. PubMed ID: 31924335
[TBL] [Abstract][Full Text] [Related]
14. The Added Value of SOX10 Immunohistochemistry to Other Breast Markers in Identifying Cytokeratin 5-Positive Triple Negative Breast Cancers as of Mammary Origin.
Sejben A; Vörös A; Golan A; Zombori T; Cserni G
Pathobiology; 2021; 88(3):228-233. PubMed ID: 33567441
[TBL] [Abstract][Full Text] [Related]
15. [Expression of SOX10 and GATA3 in breast cancer and their significance].
Liu JL; Chen DS; Cheng ZQ; Hu JT
Zhonghua Bing Li Xue Za Zhi; 2022 Jun; 51(6):536-541. PubMed ID: 35673726
[No Abstract] [Full Text] [Related]
16. TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma.
Yoon EC; Wang G; Parkinson B; Huo L; Peng Y; Wang J; Salisbury T; Wu Y; Chen H; Albarracin CT; Resetkova E; Middleton LP; Krishnamurthy S; Gan Q; Sun H; Huang X; Shen T; Chen W; Parwani AV; Sahin AA; Li Z; Ding Q
Hum Pathol; 2022 Jul; 125():97-107. PubMed ID: 35413381
[TBL] [Abstract][Full Text] [Related]
17. Folate Receptor Alpha Immunohistochemistry in Cytology Specimens of Metastatic Breast Carcinoma.
Sheikh UN; Cohen C; Siddiqui MT
Acta Cytol; 2015; 59(4):298-304. PubMed ID: 26413911
[TBL] [Abstract][Full Text] [Related]
18. A Retrospective Study of the Epidemiology, Histomorphological Features, Hormonal Status, and Radiological Features of Breast Cancer Diagnosed on Biopsies in Women in Bahrain Up to the Age of 40: A Single-Center Study.
Toorani ZA; Harb ZF; Alalawi FM; Alattar Z; Alzayani NB; Alasmawi KA; Husain R; Alsendi ME
Cureus; 2023 Nov; 15(11):e49228. PubMed ID: 38143654
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological, immunohistochemical and molecular correlation of neural crest transcription factor SOX10 expression in triple-negative breast carcinoma.
Harbhajanka A; Chahar S; Miskimen K; Silverman P; Harris L; Williams N; Varadan V; Gilmore H
Hum Pathol; 2018 Oct; 80():163-169. PubMed ID: 29894722
[TBL] [Abstract][Full Text] [Related]
20. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
